Uncoupling Hemostasis from Thrombosis: Adding Oral FXIa Inhibitor Milvexian to Antiplatelet Therapy After Acute Stroke: the AXIOMATIC-SSP trial.
Key Points Selective XIa inhibitor Milvexian may innovate the field of oral anticoagulation by uncoupling hemostasis from thrombosis and potentially providing protection... Read more.
Uncoupling Hemostasis from Thrombosis: Adding Oral FXIa Inhibitor Asundexian to Antiplatelet Therapy After Acute Non-Cardioembolic Stroke – PACIFIC-STROKE
Key Points Selective XIa inhibitor Asundexian may innovate the field of oral anticoagulation by uncoupling hemostasis from thrombosis and potentially providing protection... Read more.
An Answer at Last with INVICTUS: Patients with Rheumatic Heart Disease and Mitral Stenosis Should Remain on Warfarin, as Rivaroxaban Has a Higher Mortality Risk.
Key Points While DOACs have revolutionized the field of atrial fibrillation for patients with non-valvular disease, the equally important population of patients... Read more.
Uncoupling Hemostasis from Thrombosis: Adding Oral FXIa Inhibitor Asundexian to DAPT After Acute Myocardial Infarction – PACIFIC-AMI.
Key Points Selective XIa inhibitor Asundexian may innovate the field of oral anticoagulation by uncoupling hemostasis from thrombosis and potentially providing protection... Read more.
AI outperforms humans in LVEF assessments: EchoNet-RCT
Despite major advances in the implementation of artificial intelligence (AI) in Cardiology, from both a clinical and research perspective, no clinical trials to... Read more.
Acetazolamide results in improved decongestion, faster: results from ADVOR
Key Points: Residual decongestion after a hospitalization for acute decompensated heart failure is associated with poor outcomes. In this double-blinded, placebo-controlled... Read more.
More Evidence For the Newest Guideline Directed Medical Therapy Pillar – Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (The DELIVER Trial)
Key Points: The use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) in heart failure with preserved ejection fraction (HFpEF) has been previously established,... Read more.
No improvement with allopurinol for patients with ischemic heart disease: ALL-HEART
Key Points Allopurinol had previously shown an improvement in exercise time and qualitative chest pain assessment in patients with ischemic heart disease. ALL-HEART... Read more.
Routine PCI confers no added benefit in severe left ventricular dysfunction: REVIVED
Key Points REVIVED is the first large scale clinical trial to assess the effect of routine PCI in patients with severe left ventricular dysfunction, when compared... Read more.
Sacubitril/Valsartan has no significant effect on cognition: PERSPECTIVE
Key Points There has been a theoretical concern of potential increased amyloid deposition via neprilysin inhibition in patients using sacubitril/valsartan. In the... Read more.